<DOC>
	<DOCNO>NCT02555306</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , immunogenicity , bioactivity single intravitreal ( IVT ) administration DE-122 subject refractory exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Phase I/II Safety , Tolerability , Immunogenicity , Bioactivity Study DE-122 Injectable Solution Refractory Exudative Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Provide sign write informed consent Diagnosis subretinal intraretinal fluid secondary exudative agerelated macular degeneration Prior treatment study eye intravitreal antiVEGF medication At least one lesion study eye meet minimal pathology criterion Best correct visual acuity 65 20 ETDRS letter study eye Best correct visual acuity 20/200 good fellow eye Reasonably clear medium fixation study eye Ocular Use anticipate use intravitreal , periocular photodynamic therapy study eye treatment AMD within specify timeframe prior Visit 1 Uncontrolled advance glaucoma , chronic hypotony vitrectomy study eye Evidence ocular disease exudative agerelated macular degeneration study eye may confound outcome study Need ocular surgery study eye course study Presence history certain ocular periocular pathology condition could limit ability perform require study assessment either eye and/or confound study result NonOcular Allergy hypersensitivity study drug product , fluorescein dye studyrelated procedure medication Current history certain systemic condition , abnormality therapy would render subject poor candidate study Participation investigational drug device clinical trial within 30 day prior randomization plan participate investigational drug device clinical trial duration study Females pregnant lactating female childbearing potential use adequate contraceptive precaution men agree practice acceptable method contraception throughout course study Unable comply study procedure followup visit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Macular Degeneration</keyword>
</DOC>